Cyclessa?
(desogestrel/ethinyl estradiol tablets)
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
DRUG DESCRIPTION
Cyclessa? (desogestrel/ethinyl estradiol) Tablets are a triphasic oral contraceptive containing two active components, desogestrel and ethinyl estradiol. Each 28-day treatment cycle pack consists of three active dosing phases: 7 light yellow tablets containing 0.100 mg desogestrel (13-ethyl-11-methylene-18,19-dinor-17α -pregn-4-en-20-yn-17-ol) and 0.025 mg ethinyl estradiol (19-nor-17α -pregna-1,3,5(10)-trien-20-yne-3, 17-diol) 7 orange tablets containing 0.125 mg desogestrel and 0.025 mg ethinyl estradiol, and 7 red tablets containing 0.150 mg desogestrel and 0.025 mg ethinyl estradiol. Inactive ingredients include vitamin E, pregelatinized starch, stearic acid, lactose monohydrate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, talc, yellow ferric oxide (in light yellow and orange tablets), and red ferric oxide (in orange and red tablets). Cyclessa? also contains 7 green tablets with the following inert ingredients: lactose monohydrate, corn starch, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, FD&C Blue No. 2 aluminum lake, yellow ferric oxide, and talc.
INDICATIONS
Cyclessa? (desogestrel/ethinyl estradiol) Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptives are highly effective. Table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.